Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with BCR::ABL1-negative B-cell / myeloid mixed phenotype acute leukemia.

IF 8.2 1区医学 Q1 HEMATOLOGY

Haematologica Pub Date : 2025-06-26 DOI:10.3324/haematol.2025.287932

Roberta S Azevedo,Wei-Ying Jen,Danielle Hammond,Fadi G Haddad,Alexis Geppner,Ghayas C Issa,Koji Sasaki,Jayastu Senapati,Elias Jabbour,Farhad Ravandi,Hagop Kantarjian,Tapan M Kadia

引用次数: 0

Abstract

Not available.

查看原文本刊更多论文

在BCR:: abl1阴性的b细胞/髓细胞混合表型急性白血病患者中，低强度化学免疫治疗cladribine、低剂量阿糖胞苷、venetoclax和blinatumumab可产生高有效率。

不可用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Haematologica 医学-血液学

CiteScore

14.10

自引率

2.00%

发文量

349

审稿时长

3-6 weeks

期刊介绍： Haematologica is a journal that publishes articles within the broad field of hematology. It reports on novel findings in basic, clinical, and translational research. Scope: The scope of the journal includes reporting novel research results that: Have a significant impact on understanding normal hematology or the development of hematological diseases. Are likely to bring important changes to the diagnosis or treatment of hematological diseases.